

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Upadacitinib, abrocitinib and tralokinumab for treating moderate to severe atopic dermatitis (ID3960)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A consultee suggested that there should be special consideration given to 2 groups because of their higher needs for education and support. These groups were adolescents and “hard to reach” communities (BAME, low socio-economic backgrounds).

It was noted that because eczema has a substantial and long-term negative effect on people’s ability to carry out normal daily tasks, it is recognised as a disability under the Equality Act 2010.

Previous appraisals for this indication the committee noted that it is possible that the assessment tools for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The experiences of all people of the condition will be taken into account by the appraisal committee. The committee cannot make separate

recommendations for populations based on age or family origin and this is not considered an equality issue.

The committee should take into account skin colour and how this could affect the assessment of the severity of atopic dermatitis and response to treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not applicable

Approved by Associate Director (name): Henry Edwards

Date: 02/07/2021